Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived mesenchymal stem cells (Institute of Hematology & Blood Diseases Hospital)
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) developed by the Institute of Hematology & Blood Diseases Hospital in China. It is specifically being evaluated for the treatment of severe, long-term cytopenia following CAR-T cell therapy, a condition categorized as immune effector cell-associated hematotoxicity (ICAHT). The therapy is manufactured by UCell Life Science Development Co., Ltd. and is administered intravenously. UCB-MSCs are hypothesized to promote hematopoietic recovery and mitigate inflammatory damage within the bone marrow microenvironment through their inherent immunomodulatory and tissue-regenerative properties. The clinical development is currently focused on patients with hematologic malignancies, including acute lymphoblastic leukemia, lymphoma, and multiple myeloma, who experience persistent blood count deficiencies after receiving CAR-T cell infusions.
- Other names
- UCB-MSCsHuman umbilical cord blood-derived mesenchymal stem cells
Beyond the preview
Go deeper on umbilical cord blood-derived mesenchymal stem cells (Institute of Hematology & Blood Diseases Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived mesenchymal stem cells (Institute of Hematology & Blood Diseases Hospital).